Sumitomo Pharma Co., Ltd. (4506.T) Stock
Sumitomo Pharma Co., Ltd.

Company profile
Sumitomo Pharma reported revenue of 398.83 billion JPY for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 555.54 billion JPY in fiscal year 2023 to 398.83 billion JPY in fiscal year 2025, 15.3% a year on average.
What stands out
- Revenue rose 26.8% in fiscal year 2025, from 314.56 billion JPY in fiscal year 2024, after a fall of 43.4% the year before.
- It returned to a profit in fiscal year 2025, 23.63 billion JPY, after 2 years of net losses (314.97 billion JPY in fiscal year 2024).
- Pharmaceuticals - North America brought in 63% of segment revenue in fiscal year 2025, up from 51% in fiscal year 2024.
- The United States of America brought in 61% of revenue by region in fiscal year 2025, up from 48% in fiscal year 2024; the company is based in Japan.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Largest shareholders
- Sumitomo Chemical Company, Limited45.78%
- Sumitomo Mitsui Financial Group, Inc.1.56%
- Sumitomo Mitsui Banking Pension Fund1.56%
- Sumitomo Life Insurance Co.1.29%
- Inabata & Co.,Ltd.0.98%
Share of the company, as of September 25, 2026
Leadership
- Toru Kimura Ph.D. — President, CEO & Representative Director, 65
- Katsuhiko Nishida — EO, SVP of S&M & Head of Japan BU Deputy
- Hideyuki Harada — Mng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit
- Yumi Sato — Managing Exe. Officer of Vaccines and Adjuvants Biz Dev., Res. & Dev. Div. SVP and Head of R&D Div.
- Motoyuki Sakai — EVP of Global Corp. Strategy, Fin. Admin, Ex. Aff., CG, Corp. Comm.; IT Mgmt & DA & Rep. Director, 64
How much revenue does Sumitomo Pharma make?
Sumitomo Pharma reported 398.83 billion JPY in revenue for fiscal year 2025, up 26.8% from 314.56 billion JPY in fiscal year 2024.
What is Sumitomo Pharma's largest business segment?
Pharmaceuticals - North America, with 251.81 billion JPY or 63% of segment revenue in fiscal year 2025. Next: Pharmaceuticals - Japan (25%) and Pharmaceuticals - Asia (12%).
Where does Sumitomo Pharma make most of its revenue?
United States of America: 61% of revenue by region in fiscal year 2025, followed by Japan (23%).
What companies are similar to Sumitomo Pharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Eisai Co., Ltd. (4523.T), Kyowa Kirin Co., Ltd. (4151.T), Ono Pharmaceutical Co., Ltd. (4528.T), Nippon Shinyaku Co., Ltd. (4516.T).
How has Sumitomo Pharma's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 515.95 billion JPY; FY2022, 560.04 billion JPY; FY2023, 555.54 billion JPY; FY2024, 314.56 billion JPY; FY2025, 398.83 billion JPY.
Has Sumitomo Pharma made a profit in recent years?
Net income by fiscal year: FY2021, 56.22 billion JPY; FY2022, 56.41 billion JPY; FY2023, a loss of 74.51 billion JPY; FY2024, a loss of 314.97 billion JPY; FY2025, 23.63 billion JPY. It reported a net loss in 2 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Sumitomo Pharma Co., Ltd. (4506.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4506.T